Chest. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection

[tetano]

Chest. 2020 Mar 31. pii: S0012-3692(20)30571-7. doi: 10.1016/j.chest.2020.03.039. [Epub ahead of print]
Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection.


Zhang B¹, Liu S¹, Tan T², Huang W¹, Dong Y³, Chen L¹, Chen Q¹, Zhang L¹, Zhong Q⁴, Zhang X⁵, Zou Y⁶, Zhang S⁷.

Author information




Abstract

As of March 24, 2020, novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been responsible for 379,661 infection cases with 16,428 deaths globally and the number is still increasing rapidly. Herein, we presented four critically ill patients with SARS-CoV-2 infection who received supportive care and convalescent plasma. Although all the four patients (including a pregnant woman) recovered from SARS-CoV-2 infection eventually, randomized trials are needed to eliminate the effect of other treatments and investigate the safety and efficacy of convalescent plasma therapy.
Copyright ? 2020. Published by Elsevier Inc.



KEYWORDS:

Convalescent plasma; Critically illness; SARS-CoV-2


PMID:32243945DOI:10.1016/j.chest.2020.03.039